Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 5, 2008, Pages 705-711

  Grønbæk, Henning ^a   Thomsen, Karen Louise ^a   Rungby, Jørgen ^a   Schmitz, Ole ^a   Vilstrup, Hendrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adipocytokine; Insulin resistance; Medical treatment; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; ALPHA TOCOPHEROL; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PROBIOTIC AGENT; RIMONABANT; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONYLUREA DERIVATIVE; URSODEOXYCHOLIC ACID;

CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EDEMA; FAT INTAKE; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOKINES; DIABETES MELLITUS; DIETARY FATS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 55349104465     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.5.705     Document Type: Review

References (86)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2 Suppl. 1), S99-S112 (2006).
2. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44(4), 865-873 (2006).
3. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(1), 27-38 (2008).
4. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 21(1), 3-16 (2001).
5. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467-2474 (1999).
6. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107(5), 450-455 (1999).
7. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282(17), 1659-1664 (1999).
8. Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int. J. Obes. Relat. Metab. Disord. 22(3), 222-226 (1998).
9. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844-1850 (2001).
10. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non-diabetic patients with Nonalcoholic fatty liver disease: sites and mechanisms. Diabetologia 48(4), 634-642 (2005).
11. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98(5), 960-967 (2003).
12. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124(1), 71-79 (2003).
13. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128(3), 627-635 (2005).
14. Friedman LS, Dienstag JL, Watkins E et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann. Intern. Med. 107(2), 137-144 (1987).
15. Wejstal R, Hansson G, Lindholm A, Norkrans G. Persistent alanine aminotransferase elevation in healthy Swedish blood donors-mainly caused by obesity. Vox Sang. 55(3), 152-156 (1988).
16. Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and Type 2 diabetes in middle-aged Japanese men. Diabetes Care 27(6), 1427-1432 (2004).
17. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54(11), 3140-3147 (2005).
18. Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am. J. Clin. Nutr. 82(5), 1046-1051 (2005).
19. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6), 1387-1395 (2004).
20. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am. J. Gastroenterol. 101(1), 76-82 (2006).
21. Yoshiike N, Lwin H. Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol. Res. 33(2), 77-82 (2005).
22. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am. J. Med. Sci. 329(3), 111-116 (2005).
23. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 27(2), 142-149 (1988).
24. Franzese A, Vajro P, Argenziano A et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig. Dis. Sci. 42(7), 1428-1432 (1997).
25. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J. Pediatr. Gastroenterol. Nutr. 43(4), 413-427 (2006).
26. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118(4), 1388-1393 (2006).
27. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 22 (7), 1086-1091 (2007).
28. Suzuki A, Angulo P, Lymp J et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41(1), 64-71 (2005).
29. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115(5), 1343-1351 (2005).
30. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52(10), 2453-2460 (2003).
31. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J. Biol. Chem. 279(31), 32345-32353 (2004).
32. Pietilainen KH, Sysi-Aho M, Rissanen A et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE 2, E218-E218 (2007).
33. Westerbacka J, Lammi K, Hakkinen AM et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects, J. Clin. Endocrinol. Metab. 90(5), 2804-2809 (2005).
34. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J. Hepatol. 42(6), 928-940 (2005).
35. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36(3), 232-240 (2005).
36. Roden M. Mechanisms of disease: hepatic steatosis in Type 2 diabetes - pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2(6), 335-348 (2006).
37. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91(12), 4753-4761 (2006).
38. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40(11), 1397-1403 (1991).
39. Reitman ML. Metabolic lessons from genetically lean mice. Annu. Rev. Nutr. 22, 459-482 (2002).
40. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120(5), 1183-1192 (2001).
41. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol. 31(3), 430-434 (1999).
42. Lowell BB, Shulman GI. Mitochondrial dysfunction and Type 2 diabetes. Science 307(5708), 384-387 (2005).
43. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114(2), 147-152 (2004).
44. Petersen KF, Befroy D, Dufour S et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300(5622), 1140-1142 (2003).
45. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 54(3), 603-608 (2005).
46. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292(3), E829-E835 (2007).
47. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12(5), 1106-1110 (1990).
48. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2), 373-39 (2002).
49. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4), 917-923 (2003).
50. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (5), 987-1000 (2005).
51. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketas A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology 40(1), 46-54 (2004).
52. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90(6), 3498-3504 (2005).
53. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46(4), 459-469 (2003).
54. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8(11), 1288-1295 (2002).
55. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in Type 2 Diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 285(4), E906-E916 (2003).
56. Crespo J, Cayon A, Fernandez-Gil P et al. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34(6), 1158-1163 (2001)
57. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38(2), 413-419 (2003}
58. Fernandez-Real JM, Vayreda M, Richart C et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab. 86(3), 1154-1159 (2001).
59. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51(12), 3391-3399 (2002).
60. Yahagi N, Shimano H, Hasty AH et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep (ob)/Lep (ob) mice. J. Biol. Chem. 277(22), 19353-19357 (2002).
61. Kim JB, Wright HM, Wright M, Spiegelman BM. ADDI/SREBP1 activates PPARγ through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA 95(8), 4333-4337 (1998).
62. Fajas L, Schoonjans K, Gelman L et al. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol. 19(8), 5495-5503 (1999).
63. Kolehmainen M, Vidal H, Alhava E, Uusitupa MI. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity. Obes. Res. 9(11), 706-712 (2001).
64. Denechaud PD, Dentin R, Giram J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett. 582(1), 68-73 (2008).
65. Postic C, Dentin R, Denechaud PD, Giram J. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu. Rev. Nutr. 27, 179-192 (2007).
66. Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104(31), 12587-12594 (2007).
67. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease, Gastroenterology 132(6), 2191-2207 (2007).
68. Seppala-Lindroos A, Vehkavaara S, Haktdnen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87(7), 3023-3028 (2002).
69. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature 444(7121), 840-846 (2006).
70. Adams LA, Angulo P. Treatment of nonalcoholic fatty liver disease. Postgrad. Med. J. 82(967), 315-322 (2006).
71. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53(3), 413-419 (2004).
72. Tiikkainen M, Bergholm R, Vehkavaara S et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52(3), 701-707 (2003).
73. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (22), 2297-2307 (2006).
74. Akyuz F, Demir K, Ozdil S et al. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52(9), 2359-2367 (2007).
75. Lutchman G, Promrat K, Kleiner DE et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 4(8), 1048-1052 (2006).
76. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100(5), 1082-1090 (2005).
77. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database Syst. Rev. (1), CD005166 (2007).
78. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292(3), E829-E835 (2007).
79. Katoh S, Hata S, Matsushima M et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 50(4), 414-417 (2001).
80. Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (1), CD005160 (2007).
81. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. (1), CD004996 (2007).
82. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22(5), 634-638 (2007).
83. Guallar E, Hanley DF, Miller ER 3rd. An editorial update: Annus horribilis for vitamin E. Ann. Intern. Med 143(2), 143-145 (2005).
84. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 47(1), 135-141 (2007).
85. Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12(6), 671-676 (2006).
86. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 26(8), 1015-1017 (2006).